Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Publication | Closed Access

DOI

Citations

References

2020

Year

Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Mónica Galli, Francesco Di Raimondo, Claudia Crippa, Mario Boccadoro,

The Lancet Haematology

Hematological MalignancyTransplantationMarrow TransplantationMedicineRandomised Phase 3ImmunologyHematologyPathologyOpen-label StudyMultiple MyelomaRadiation OncologyOncologyCell TransplantationMyelopoiesisHealth Sciences